Reply

Affiliations

¹ Resolve Therapeutics, St. Petersburg, FL.
² NIHR Birmingham Biomedical Research Centre University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
³ Newcastle University and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK.

Comment

James Posada et al. Arthritis Rheumatol. 2021 Apr.

. 2021 Apr;73(4):718-719.

doi: 10.1002/art.41581. Epub 2021 Feb 18.

¹ Resolve Therapeutics, St. Petersburg, FL.
² NIHR Birmingham Biomedical Research Centre University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
³ Newcastle University and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK.

No abstract available

Comment on

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F, Fisher BA, Ng WF. Posada J, et al. Arthritis Rheumatol. 2021 Jan;73(1):143-150. doi: 10.1002/art.41489. Epub 2020 Nov 22. Arthritis Rheumatol. 2021. PMID: 32798283 Free PMC article. Clinical Trial.
Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al.
Chiche L, Jourde-Chiche N, Cornec D. Chiche L, et al. Arthritis Rheumatol. 2021 Apr;73(4):717-718. doi: 10.1002/art.41582. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33164342 No abstract available.

1. Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, et al. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol 2019;1:E85-94.